Kyle Cromer, PhD

Title(s)Assistant Professor, Surgery
SchoolSchool of Medicine
AddressLocation Required, #001
ORCID ORCID Icon0000-0002-8198-5010 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Yale University, New Haven, CTPhD05/2014Genetics
    Harvard Medical School, Boston, MAPostdoc05/2016Genetics
    Stanford University, Stanford, CAPostdoc06/2020Pediatrics
    Stanford University, Stanford, CAInstructor05/2022Pediatrics
    Collapse Awards and Honors
    UCSF Innovation Ventures2024  - 2025Catalyst Award
    UCSF School of Pharmacy2024  - 2025Mary Anne Koda-Kimble Award
    American Society of Hematology2023  - 2024Junior Faculty Scholar Award
    UCSF Program for Breakthrough Biomedical Research2023  - 2024New Frontier Research Award
    American Society of Gene & Cell Therapy2022  - 2022Career Development Award
    Stanford Bio-X2021  - 2021Star Mentor Award
    Prix Ars Electronica2021  - 2021Honorary Mention

    Collapse Overview 
    Collapse Overview
    While we have long known the location of disease-causing mutations in the genome, the discovery of CRISPR finally gave us the ability to correct these typos back to what they should be in healthy patients. While this effort has yielded novel therapies in the clinic, in my own lab I want to look beyond simply correcting DNA typos and instead use genome editing to introduce novel functions into cells for therapeutic purposes.
    Examples include:
    -Engineering red blood cells to deliver novel protein payloads
    -Creating genome editing strategies that bias stem cell differentiation to produce clinically relevant cell types
    -Engineering kill switches to prevent differentiation into unwanted cell types
    -Developing novel ways to regulate therapeutic protein stability and expression using small molecules
    -Multiplexing editing in order to introduce multiple genome editing events simultaneously (such as correcting a disease-causing mutation and adding a kill switch that could be activated in the case of an adverse event)

    With special focus on hematopoietic stem cells and red blood cells, my main goal is to close the gap between synthetic biologists and clinicians in order to address current bottlenecks in treating the hemoglobinopathies and other blood disorders. While this is my current focus, the tools I am developing are cell type- and disease-agnostic and I am always open to expanding these concepts into new areas.
    Collapse Websites

    Collapse Research 
    Collapse Research Activities and Funding
    Enrichment of erythroid cells using truncated EPO receptor
    American Society of Hematology Junior Faculty Scholar AwardJul 1, 2023 - Jun 28, 2026
    Role: Principal Investigator
    Developing base editor-mediated correction strategies for a-thalassemia
    UCSF Living Therapeutics Initiative Preclinical GrantJul 1, 2023 - Jun 28, 2025
    Role: Principal Investigator
    Development of inducible signaling receptors to increase production of clinically relevant cell types
    UCSF Program for Breakthrough Biomedical Research New Frontier Research AwardJun 1, 2023 - May 30, 2024
    Role: Principal Investigator
    Developing gene therapy strategies to correct a-thalassemia
    NIH NHLBI R01 - HL161291Jan 1, 2022 - Dec 31, 2025
    Role: Co-Investigator
    Description: The goal of this proposal is to develop homologous recombination-mediated genome editing to restore alpha-globin levels in patients suffering from alpha-thalassemia.
    Developing a CRISPR/AAV-mediated genome editing strategy to correct a-thalassemia
    American Society of Gene & Cell Therapy Career Development AwardJan 1, 2022 - Dec 31, 2022
    Role: Principal Investigator
    Description: The goal of this proposal is to develop homologous recombination-mediated genome editing to restore alpha-globin levels in patients suffering from alpha-thalassemia.

    Collapse ORNG Applications 
    Collapse Featured Publications

    Collapse Featured Content 
    Collapse Twitter

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Comparative analysis of CRISPR off-target discovery tools following ex vivo editing of CD34+ hematopoietic stem and progenitor cells. Mol Ther. 2023 Apr 05; 31(4):1074-1087. Cromer MK, Majeti KR, Rettig GR, Murugan K, Kurgan GL, Bode NM, Hampton JP, Vakulskas CA, Behlke MA, Porteus MH. PMID: 36793210; PMCID: PMC10124080.
      View in: PubMed   Mentions: 2     Fields:    
    2. Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells. Nat Commun. 2022 Aug 11; 13(1):4724. Cromer MK, Barsan VV, Jaeger E, Wang M, Hampton JP, Chen F, Kennedy D, Xiao J, Khrebtukova I, Granat A, Truong T, Porteus MH. PMID: 35953477; PMCID: PMC9372057.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    3. Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Sci Transl Med. 2021 06 16; 13(598). Lattanzi A, Camarena J, Lahiri P, Segal H, Srifa W, Vakulskas CA, Frock RL, Kenrick J, Lee C, Talbott N, Skowronski J, Cromer MK, Charlesworth CT, Bak RO, Mantri S, Bao G, DiGiusto D, Tisdale J, Wright JF, Bhatia N, Roncarolo MG, Dever DP, Porteus MH. PMID: 34135108; PMCID: PMC8862191.
      View in: PubMed   Mentions: 51     Fields:    Translation:HumansAnimalsCells
    4. Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells. Nat Med. 2021 04; 27(4):677-687. Cromer MK, Camarena J, Martin RM, Lesch BJ, Vakulskas CA, Bode NM, Kurgan G, Collingwood MA, Rettig GR, Behlke MA, Lemgart VT, Zhang Y, Goyal A, Zhao F, Ponce E, Srifa W, Bak RO, Uchida N, Majeti R, Sheehan VA, Tisdale JF, Dever DP, Porteus MH. PMID: 33737751; PMCID: PMC8265212.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansAnimalsCells
    5. Improved Genome Editing through Inhibition of FANCM and Members of the BTR Dissolvase Complex. Mol Ther. 2021 03 03; 29(3):1016-1027. de Alencastro G, Puzzo F, Pavel-Dinu M, Zhang F, Pillay S, Majzoub K, Tiffany M, Jang H, Sheikali A, Cromer MK, Meetei R, Carette JE, Porteus MH, Pekrun K, Kay MA. PMID: 33678249; PMCID: PMC7934449.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    6. Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguards. Nat Commun. 2020 06 01; 11(1):2713. Martin RM, Fowler JL, Cromer MK, Lesch BJ, Ponce E, Uchida N, Nishimura T, Porteus MH, Loh KM. PMID: 32483127; PMCID: PMC7264334.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    7. Highly Efficient and Marker-free Genome Editing of Human Pluripotent Stem Cells by CRISPR-Cas9 RNP and AAV6 Donor-Mediated Homologous Recombination. Cell Stem Cell. 2019 05 02; 24(5):821-828.e5. Martin RM, Ikeda K, Cromer MK, Uchida N, Nishimura T, Romano R, Tong AJ, Lemgart VT, Camarena J, Pavel-Dinu M, Sindhu C, Wiebking V, Vaidyanathan S, Dever DP, Bak RO, Laustsen A, Lesch BJ, Jakobsen MR, Sebastiano V, Nakauchi H, Porteus MH. PMID: 31051134.
      View in: PubMed   Mentions: 92     Fields:    Translation:HumansCells
    8. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat Med. 2019 02; 25(2):249-254. Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart VT, Cromer MK, Vakulskas CA, Collingwood MA, Zhang L, Bode NM, Behlke MA, Dejene B, Cieniewicz B, Romano R, Lesch BJ, Gomez-Ospina N, Mantri S, Pavel-Dinu M, Weinberg KI, Porteus MH. PMID: 30692695; PMCID: PMC7199589.
      View in: PubMed   Mentions: 375     Fields:    Translation:HumansCells
    9. Global Transcriptional Response to CRISPR/Cas9-AAV6-Based Genome Editing in CD34+ Hematopoietic Stem and Progenitor Cells. Mol Ther. 2018 10 03; 26(10):2431-2442. Cromer MK, Vaidyanathan S, Ryan DE, Curry B, Lucas AB, Camarena J, Kaushik M, Hay SR, Martin RM, Steinfeld I, Bak RO, Dever DP, Hendel A, Bruhn L, Porteus MH. PMID: 30005866; PMCID: PMC6171165.
      View in: PubMed   Mentions: 57     Fields:    Translation:HumansCells
    10. Priming Human Repopulating Hematopoietic Stem and Progenitor Cells for Cas9/sgRNA Gene Targeting. Mol Ther Nucleic Acids. 2018 Sep 07; 12:89-104. Charlesworth CT, Camarena J, Cromer MK, Vaidyanathan S, Bak RO, Carte JM, Potter J, Dever DP, Porteus MH. PMID: 30195800; PMCID: PMC6023838.
      View in: PubMed   Mentions: 45  
    11. Neomorphic effects of recurrent somatic mutations in Yin Yang 1 in insulin-producing adenomas. Proc Natl Acad Sci U S A. 2015 Mar 31; 112(13):4062-7. Cromer MK, Choi M, Nelson-Williams C, Fonseca AL, Kunstman JW, Korah RM, Overton JD, Mane S, Kenney B, Malchoff CD, Stalberg P, Akerström G, Westin G, Hellman P, Carling T, Björklund P, Lifton RP. PMID: 25787250; PMCID: PMC4386328.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    12. Identification of somatic mutations in parathyroid tumors using whole-exome sequencing. J Clin Endocrinol Metab. 2012 Sep; 97(9):E1774-81. Cromer MK, Starker LF, Choi M, Udelsman R, Nelson-Williams C, Lifton RP, Carling T. PMID: 22740705; PMCID: PMC5393442.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    Kyle's Networks
    Concepts (92)
    Derived automatically from this person's publications.
    Similar People (60)
    People who share similar concepts with this person.
    Same Department
    Search Department